# Camizestrant

Source: https://onco.cc/drugs/camizestrant/  
OnCo record `camizestrant` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.

## Summary

Camizestrant is AstraZeneca's next-generation oral SERD. SERENA-6 randomised patients whose ctDNA acquired an ESR1 mutation during first-line AI + CDK4/6 to switch to camizestrant + CDK4/6: PFS 16.0 vs 9.2 months (HR 0.44). After a 6-3 negative ODAC vote (April 2026) over the clinical meaning of acting on ctDNA, FDA granted accelerated approval on 4 September 2026, the first indication triggered by a molecular rather than radiographic event. SERENA-4 (first-line, unselected) and the adjuvant CAMBRIA trials will define its wider role.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Etcamah
- Code: AZD9833
- Modality: Oral SERD
- Mechanism: Oral SERD: ER antagonist and degrader active against wild-type and ESR1-mutant receptors.
- Approvals: US 2026: HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026); EU 2026: ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026
- Dosing: Oral; 75 mg once daily with a CDK4/6 inhibitor (per SERENA-6)
- Toxicity (grade 3+): Neutropenia (with CDK4/6) 45%

## Sources

- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Camizestrant

## Connected records

- pairings: [Oral SERD + CDK4/6 inhibitor after ESR1 emergence](https://onco.cc/pairings/oral-serd-plus-cdk46-after-esr1/)
- cancers: [High-risk early HR-positive breast cancer](https://onco.cc/cancers/hr-positive-early-high-risk/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [HR-positive metastatic breast cancer after CDK4/6 inhibitors](https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Oral SERDs](https://onco.cc/technologies/oral-serds/)
- targets: [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [ESR1 mutation](https://onco.cc/terms/esr1-mutation/), [Oral SERD](https://onco.cc/terms/oral-serd/)
- trials: [A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease](https://onco.cc/trials/nct04711252/), [A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ](https://onco.cc/trials/nct06188520/), [A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer](https://onco.cc/trials/nct07647328/), [A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy](https://onco.cc/trials/nct05774951/), [A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer](https://onco.cc/trials/nct04214288/), [CAMBRIA-1 & CAMBRIA-2](https://onco.cc/trials/cambria/), [Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer](https://onco.cc/trials/nct06380751/), [SERENA-6](https://onco.cc/trials/serena-6/), [Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct04644068/), [Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer](https://onco.cc/trials/nct07427394/)
- ideas: [Intercepting late recurrence with ctDNA surveillance and oral SERDs](https://onco.cc/ideas/idea-late-recurrence-interception/), [Molecular-progression switching beyond ESR1](https://onco.cc/ideas/idea-ctdna-switch-generalised/)
- people: [Nicholas Turner](https://onco.cc/people/nicholas-turner/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/)
- biomarkers: [ESR1 mutation (ligand-binding domain, usually in ctDNA)](https://onco.cc/biomarkers/esr1-mutation-ctdna/)
- roadmaps: [Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test](https://onco.cc/roadmaps/hormonal-therapy-roadmap/)
- pathways: [Breast cancer (KEGG map)](https://onco.cc/pathways/breast-cancer-signalling/)

---
JSON: https://onco.cc/api/v1/entities/camizestrant.json